Biotech Merger Fuels Drug Development
NextCure and Avere Merge, Secure $320M to Accelerate AVR-001 Drug Development
Anonymous
Key Points
1
The private financing accompanying the merger includes $251 million of convertible notes that will be exchanged into common stock as part of the $320 million private placement, providing a structured funding path to advance AVR-001 through Phase 2b and into Phase 3 and ulcerative colitis studies.
2
The Avere leadership team brings a proven track record from Akero Therapeutics, with Andrew Cheng, Kitty Yale, and William White having guided Akero from pre-IPO to a sale to Novo Nordisk for up to $5.2 billion in December 2025.
3
AVR-001 is described as an extended half-life, once-weekly oral IL-23 receptor antagonist, a design feature supported by Hansoh’s licensing discussions and its Phase 1b data in psoriasis.
4
The deal will be completed via a reverse merger with NextCure, with the merged company expected to list on Nasdaq as AVRX, highlighting the merger path rather than a traditional IPO.
NextCure and privately-held Avere Therapeutics have agreed to merge in an all-stock deal, pairing up to bring Avere's once-weekly oral drug AVR-001 to market faster, according to Nasdaq. The combined company will trade on Nasdaq under the ticker AVRX and carry the Avere Therapeutics name.
The merger comes with roughly $320 million in private financing, including $251 million in convertible notes that will convert into common stock, reports Pharmaphorum. That cash is meant to fund AVR-001 through Phase 2b trials and into Phase 3 studies for psoriasis and ulcerative colitis.
AVR-001 Targets a Proven Immune Pathway Orally
AVR-001 blocks IL-23, the immune signal behind diseases like psoriasis and ulcerative colitis. Most existing IL-23 blockers are injected biologics. AVR-001 is taken by mouth once a week, which could make it far easier for patients to use, Pharmaphorum noted.
The drug already has Phase 1b data in psoriasis patients showing it works. A global Phase 2b psoriasis study is planned to start in 2027, with results expected in early 2028, according to Nasdaq. A Phase 2b ulcerative colitis study is also set to begin around the same time.
Hansoh Pays $120 Million to License AVR-001 Rights
China's Hansoh Pharmaceutical has already bet big on AVR-001. The company paid $120 million upfront to license the drug's rights outside Greater China. The deal could be worth up to $2.18 billion more in milestone payments, plus royalties, Nasdaq reported.
That licensing deal signals outside confidence in AVR-001 before the merger even closes. It also gives the new Avere Therapeutics a near-term cash injection to pair with its $320 million private raise, helping fund a busy clinical calendar through 2028.
Akero Therapeutics Veterans Will Run the New Company
Andrew Cheng will lead the merged company as CEO, joined by Kitty Yale and William White. All three ran Akero Therapeutics together before Novo Nordisk bought Akero for up to $5.2 billion in December 2025, according to Pharmaphorum.
That Akero exit gives the Avere team a strong track record with investors. Building a biotech from pre-IPO to a multibillion-dollar sale shows they know how to move a drug program forward and find a buyer, a key selling point for a company that still needs to run expensive late-stage trials.
NextCure Shareholders Get a Small but Protected Stake
The deal is structured as a reverse merger, using NextCure's Nasdaq listing as the vehicle rather than launching a traditional IPO, GuruFocus reported. NextCure shareholders are projected to own about 1.21% of the combined company after the deal closes.
To sweeten that small stake, NextCure holders will also receive a contingent value right, or CVR. The CVR gives them 90% of any proceeds from monetizing certain NextCure pipeline assets, according to Benzinga. The deal is expected to close in the second half of 2026.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
21
Articles
40
Reach
61
A
AnonymousAuthor